Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 5,146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Active, not recruiting No phase listed Observational

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

NCT02389595
View directory record Official record
Conditions
HIV
Interventions
HIV positive subjects, Non-infected control subjects
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 3 Interventional Results available

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT03945981
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir + Lamivudine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 3 Interventional Results available

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

NCT00537394
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Raltegravir, Darunavir, Tipranavir, Etravirine, Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
61
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Not applicable Interventional Results available

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

NCT03864653
View directory record Official record
Conditions
HIV/AIDS, Methamphetamine Abuse, Depression
Interventions
MoodGym
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 23, 2026, 8:36 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long-Term Effects of HIV Exposure and Infection in Children

NCT00006304
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Hours to 21 Years
Enrollment
4,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining Hair to Determine Tenofovir Exposure

NCT00903084
View directory record Official record
Conditions
HIV
Interventions
Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Not applicable Interventional

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

NCT00002306
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

NCT03110549
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
TMB-607, Placebo
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Crossover Study Evaluating 3 Non-medicated Silicone IVRs

NCT05128136
View directory record Official record
Conditions
Hiv, Pregnancy Related
Interventions
Impact of ring size on adherence
Device
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 23, 2026, 8:36 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

NCT07349758
View directory record Official record
Conditions
Healthy Volunteer, HIV Prevention
Interventions
tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed No phase listed Observational

A Study of the Long-Term Outcomes of HIV-Positive Patients

NCT00000932
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
91
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 23, 2026, 8:36 AM EDT
Active, not recruiting Phase 2 Interventional

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

NCT05382208
View directory record Official record
Conditions
Emphysema, HIV
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research

NCT03049904
View directory record Official record
Conditions
HIV, Substance Use
Interventions
Vr2L 2Spirit
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 4 Interventional

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

NCT04388904
View directory record Official record
Conditions
HIV-1-infection
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Drug
Lead sponsor
The Crofoot Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Results available

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

NCT00285584
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Bupropion, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

NCT00013585
View directory record Official record
Conditions
Cognition Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 23, 2026, 8:36 AM EDT
Not listed Phase 2 Interventional

The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1

NCT00227825
View directory record Official record
Conditions
Adherence, HIV Risk Behaviors, Alcohol & Drug Use, Health Behaviors, Sexual Risk Behaviors
Interventions
Motivational interviewing
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
16 Years to 24 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 8:36 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

HIV Testing in Community Health Center Dental Clinics

NCT07089849
View directory record Official record
Conditions
HIV
Interventions
Rapid HIV testing, Referral for HIV testing
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
6,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Dorchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 8:36 AM EDT
Not listed Phase 4 Interventional

Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

NCT02800655
View directory record Official record
Conditions
HIV
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 23, 2026, 8:36 AM EDT
Completed Not applicable Interventional

Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS

NCT00000693
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 8:36 AM EDT
Not listed Phase 4 Interventional

Buprenorphine and Integrated HIV Care Evaluation

NCT00124358
View directory record Official record
Conditions
Opioid-Related Disorders, HIV Infections, AIDS
Interventions
Buprenorphine, Integrated HIV care and office-based opioid dependence treatment
Drug · Behavioral
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2007 · Synced Oct 23, 2026, 8:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

NCT06266416
View directory record Official record
Conditions
Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Interventions
IMARA for Black Male Caregivers and Girls Empowerment, Time-matched control program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
13 Years and older
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 8:36 AM EDT